Literature DB >> 11798981

Polymyalgia rheumatica/temporal arteritis: recent advances.

Maria-Louise Barilla-LaBarca1, Deborah J Lenschow, Richard D Brasington.   

Abstract

Polymyalgia rheumatica (PMR)/temporal arteritis (TA) frequently causes significant morbidity in patients older than 50 years of age. This review highlights recent trends in clinical findings, epidemiology, pathogenesis, and laboratory and radiologic assessment of the disease. Although steroids are the mainstay of therapy because of their effectiveness and ease of administration, they have numerous side effects, particularly in an aging population. Furthermore, recent evidence suggests that steroids only suppress clinical symptoms, while a smoldering level of damaging vascular inflammation persists. As a result, alternative agents are actively being investigated. We compare their successes and shortcomings and offer insight into their potential role in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11798981     DOI: 10.1007/s11926-002-0022-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  51 in total

1.  Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch.

Authors:  D Blockmans; S Stroobants; A Maes; L Mortelmans
Journal:  Am J Med       Date:  2000-02-15       Impact factor: 4.965

2.  Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

Authors:  G G Hunder; S G Sheps; G L Allen; J W Joyce
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

3.  Antibodies against Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica.

Authors:  A Uddhammar; J Boman; P Juto; S Rantapää Dahlqvist
Journal:  Clin Exp Rheumatol       Date:  1997 May-Jun       Impact factor: 4.473

4.  Sulfamethoxazole/trimethoprim therapy for polymyalgia rheumatica. Report of 5 cases.

Authors:  N Galezowski; T B Nguyen; P Blanche
Journal:  J Rheumatol       Date:  1997-07       Impact factor: 4.666

5.  The use of methotrexate in polymyalgia rheumatica.

Authors:  H L Feinberg; J D Sherman; C G Schrepferman; C J Dietzen; G D Feinberg
Journal:  J Rheumatol       Date:  1996-09       Impact factor: 4.666

6.  Proximal bursitis in active polymyalgia rheumatica.

Authors:  C Salvarani; F Cantini; I Olivieri; L Barozzi; L Macchioni; L Niccoli; A Padula; M De Matteis; P Pavlica
Journal:  Ann Intern Med       Date:  1997-07-01       Impact factor: 25.391

7.  Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity?

Authors:  F Liozon; E Vidal; J Barrier
Journal:  Clin Exp Rheumatol       Date:  1993 Nov-Dec       Impact factor: 4.473

8.  The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica.

Authors:  P Doury; S Pattin; F Eulry; A Thabaut
Journal:  Arthritis Rheum       Date:  1983-05

Review 9.  Spectrum of giant cell vasculitis.

Authors:  N Mohan; G Kerr
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

10.  Prevention of blindness in giant cell arteritis by corticosteroid treatment.

Authors:  A B Myles; T Perera; M G Ridley
Journal:  Br J Rheumatol       Date:  1992-02
View more
  3 in total

1.  Headache Caused by Giant Cell Arteritis.

Authors:  Thomas N Ward; Morris Levin; Robert L Wong
Journal:  Curr Treat Options Neurol       Date:  2004-11       Impact factor: 3.598

Review 2.  Horton's disease: past and present.

Authors:  Morris Levin; Thomas N Ward
Journal:  Curr Pain Headache Rep       Date:  2005-08

Review 3.  Granulomatous vasculitis.

Authors:  Javier Marquez; Diana Flores; Liliana Candia; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.